BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc.
TypePublic
Nasdaq: BCRX
Russell 2000 Component
IndustryHealthcare
Founded1986 (1986)
HeadquartersDurham, North Carolina, US
Key peopleCharlie Gayer (president and CEO)
ProductsORLADEYO, RAPIVAB
RevenueIncrease $874.9 million (2025)
Number of employees
450
Websitewww.biocryst.com

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.